Serum transthyretin as a staging biomarker in ATTR cardiomyopathy: promise, limitations, and the path forward

Scritto il 13/07/2026
da Valentina Allegro

No abstract

Eur J Heart Fail. 2026 Jul 13:xuag200. doi: 10.1093/ejhf/xuag200. Online ahead of print.

NO ABSTRACT

PMID:42441529 | DOI:10.1093/ejhf/xuag200